You need to be logged in to view this video

An Overview of Lexaria Bioscience

Released on Tuesday, July 13, 2021BIOTECH

Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECHTM, has repeatedly demonstrated, with cannabinoids and nicotine, the ability to increase bio-absorption by up to 5-10x, reduce time of onset from 1-2 hours to just minutes, and mask unwanted tastes since 2016. DehydraTECHTM is being evaluated for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), and nicotine.

Some of Lexaria's 2021 applied research and development milestones include:

  • HYPER-A21-2 - DehydraTECHTM formulations deliver the strongest absorption enhancement results the company has ever recorded, at 2,708% more CBD into bloodstream during the study period than the representative industry standard MCT control formulation.
  • VIRAL-C21-3 - Determined antiviral drugs processed with DehydraTECHTM were effective at inhibiting the COVID-19 SARS-CoV-2 virus.
  • VIRAL-A20-2 - Circulating drug levels in the bloodstream that are twice or even three-times higher with DehydraTECHTM than without.

Chris Bunka
Lexaria Bioscience Corp., CEO and Chairman

Trending Now

Filter By Category
Filter By Keywords
Live Now

Accredited Investors Virtual Expo

July 27 - 29, 2021